CDC25 Cancer Research Results

CDC25, Cell Division Cycle 25: Click to Expand ⟱
Source:
Type:
CDC25 (Cell Division Cycle 25) is a family of dual-specificity phosphatases that play a crucial role in regulating the cell cycle. There are three main isoforms of CDC25: CDC25A, CDC25B, and CDC25C. These proteins are involved in the activation of cyclin-dependent kinases (CDKs) by dephosphorylating them, which is essential for the progression of the cell cycle from G2 phase to mitosis.
CDC25 proteins, particularly CDC25A, are often found to be overexpressed in various types of cancer. This overexpression can lead to uncontrolled cell proliferation, as the normal regulatory mechanisms of the cell cycle are disrupted.
High levels of CDC25 have been associated with advanced stages of cancer and poor prognosis in several malignancies, including breast, colorectal, and prostate cancers.
CDC25 interacts with various oncogenes and tumor suppressor proteins, such as p53. The loss of p53 function, which is common in many cancers, can lead to increased CDC25 activity, further promoting tumorigenesis.
CDC25A overexpressed: breast, CRC, lung, prostate.
CDC25B: breast, ovarian, lung.
CDC25C: liver,breast, prostate.
IBD, Inflammatory Bowel Disease: Click to Expand ⟱
Inflammatory Bowel Disease

The main pathways involved in IBD include intestinal barrier dysfunction, mucus barrier impairment, dysbiosis-driven innate immune activation, and persistent cytokine-mediated inflammation. Key barrier components such as ZO-1, occludin, claudins, and MUC2 are commonly disrupted, increasing epithelial permeability and microbial translocation. This promotes activation of inflammatory hubs including TNF-α, NF-κB, IL-1β, IL-6/STAT3, and IL-23/Th17, while JAK/STAT signaling integrates multiple cytokine inputs that sustain chronic mucosal injury. Together, these pathways drive epithelial damage, immune dysregulation, and failure of mucosal healing in ulcerative colitis and Crohn’s disease

Rank Pathway / Axis Representative Targets / Markers Typical Direction in IBD Main Relevance
1 Intestinal Barrier Integrity / Tight Junctions ZO-1 (TJP1), Occludin (OCLN), Claudins (especially CLDN2, CLDN1) ZO-1 ↓, OCLN ↓, barrier loosened; CLDN2 often ↑ Core barrier failure increases intestinal permeability, microbial entry, and chronic inflammation
2 Mucus Barrier / Goblet Cell Axis MUC2, goblet cells, antimicrobial peptides MUC2 and goblet protection often impaired Weak mucus defense exposes the epithelium to luminal bacteria and antigens
3 TNF-α Inflammatory Axis TNF-α, TNFR1, TNFR2 ↑ Major inflammatory driver and validated therapeutic target in IBD
4 NF-κB Signaling NF-κB, IKK, IκB, COX-2, iNOS ↑ Central transcriptional hub for cytokines, chemokines, and inflammatory amplification
5 IL-23 / Th17 Axis IL-23, IL-23R, IL-17A, IL-22, RORγt ↑ / dysregulated Important bridge between innate and adaptive immune inflammation
6 JAK / STAT Signaling JAK1, JAK2, TYK2, STAT3 ↑ / activated Integrates multiple cytokine signals that sustain mucosal inflammation
7 IL-6 / STAT3 Axis IL-6, IL-6R, gp130, STAT3 ↑ Supports inflammatory persistence, immune-cell survival, and epithelial injury signaling
8 IL-1β / Inflammasome Axis IL-1β, NLRP3, ASC, caspase-1 ↑ Promotes innate inflammation, cytokine escalation, and epithelial damage
9 Microbiota / Dysbiosis / PRR Signaling Dysbiosis, TLRs, MyD88, LPS-related signaling Dysregulated / activated Links altered microbiota to barrier loss and immune activation
10 Oxidative Stress / Redox Imbalance ROS, lipid peroxidation, MPO, antioxidant defenses ↑ oxidative stress Contributes to epithelial injury, inflammatory signaling, and impaired healing
11 Leukocyte Trafficking / Adhesion Integrins, MAdCAM-1, ICAM-1, VCAM-1, chemokines ↑ Drives immune-cell recruitment into inflamed intestinal tissue
12 Epithelial Apoptosis / Restitution / Mucosal Healing Caspases, repair pathways, epithelial proliferation and restitution markers Injury ↑, healing impaired Determines whether mucosal damage resolves or progresses to chronic disease
Rank Natural Product Best Fit in IBD Evidence Level Main Rationale Notes
1 Curcumin Mainly Ulcerative Colitis (UC) Best human evidence Strongest overall adjunctive clinical support among common natural products for active UC Anti-inflammatory; NF-κB / cytokines / oxidative stress; mucosal support
2 Indigo naturalis (Qing Dai) Mainly UC Strong efficacy, safety-limited Good human efficacy signals, but safety concerns lower practical rank Anti-colitic; immune/inflammatory modulation; use caution flag for safety
3 Boswellia serrata UC / colitis Older smaller human trials Suggestive remission data and anti-inflammatory relevance, but evidence base is limited 5-LOX / leukotrienes / inflammation / mucosal protection
4 Aloe vera gel Mild-to-moderate UC Small human trial signal Some human improvement signal, though not as strong as curcumin or indigo naturalis Mucosal soothing / anti-inflammatory / healing support
5 Andrographis paniculata / andrographolide Mostly UC Mixed human, stronger preclinical Mechanistically promising, but human benefit is less consistent NF-κB / cytokines / barrier and anti-inflammatory support
6 Carvacrol Experimental colitis / dysbiosis / barrier dysfunction Preclinical Promising anti-colitis terpene with anti-inflammatory, antioxidant, and microbiota-related effects Dysbiosis / intestinal barrier integrity / NF-κB / oxidative stress
7 Thymol Experimental colitis / barrier dysfunction Preclinical Promising anti-colitis terpene with cytokine suppression and NF-κB-related effects Dysbiosis / intestinal barrier integrity / NF-κB / COX-2 / oxidative stress
8 Carvacrol + Thymol Experimental colitis, dysbiosis, bile-acid modulation Preclinical, mechanistically strong Combination may be especially relevant due to microbiota and bile-acid pathway effects in DSS colitis Bifidobacterium / secondary bile acids / barrier support / anti-colitic signaling
9 Peppermint oil Supportive / experimental colitis / GI symptom relief Mainly preclinical for IBD; stronger IBS evidence Menthol-rich oil with anti-inflammatory, antispasmodic, and possible barrier-supportive effects, but limited direct human IBD evidence Menthol / TRP modulation / cytokines / oxidative stress / GI symptom support


Scientific Papers found: Click to Expand⟱
2674- BBR,    Berberine: A novel therapeutic strategy for cancer
- Review, Var, NA - Review, IBD, NA
Inflam↓, AntiCan↑, Apoptosis↑, TumAuto↑, TumCCA↑, TumMeta↓, TumCI↓, eff↑, eff↑, CD4+↓, TNF-α↓, IL1↓, BioAv↓, BioAv↓, other↓, AMPK↑, MAPK↓, NF-kB↓, IL6↓, MCP1↓, PGE2↓, COX2↓, *ROS↓, *antiOx↑, *GPx↑, *Catalase↑, AntiTum↑, TumCP↓, angioG↓, Fas↑, FasL↑, ROS↑, ATM↑, P53↑, RB1↑, Casp9↑, Casp8↑, Casp3↓, BAX↑, Bcl-2↓, Bcl-xL↓, IAP1↓, XIAP↓, survivin↓, MMP2↓, MMP9↓, CycB/CCNB1↓, CDC25↓, CDC25↓, Cyt‑c↑, MMP↓, RenoP↑, mTOR↓, MDM2↓, LC3II↑, ERK↓, COX2↓, MMP3↓, TGF-β↓, EMT↑, ROCK1↓, FAK↓, RAS↓, Rho↓, NF-kB↓, uPA↓, MMP1↓, MMP13↓, ChemoSen↑,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

ROS↑, 1,  

Mitochondria & Bioenergetics ⓘ

CDC25↓, 2,   MMP↓, 1,   XIAP↓, 1,  

Core Metabolism/Glycolysis ⓘ

AMPK↑, 1,  

Cell Death ⓘ

Apoptosis↑, 1,   BAX↑, 1,   Bcl-2↓, 1,   Bcl-xL↓, 1,   Casp3↓, 1,   Casp8↑, 1,   Casp9↑, 1,   Cyt‑c↑, 1,   Fas↑, 1,   FasL↑, 1,   IAP1↓, 1,   MAPK↓, 1,   MDM2↓, 1,   survivin↓, 1,  

Transcription & Epigenetics ⓘ

other↓, 1,  

Autophagy & Lysosomes ⓘ

LC3II↑, 1,   TumAuto↑, 1,  

DNA Damage & Repair ⓘ

ATM↑, 1,   P53↑, 1,  

Cell Cycle & Senescence ⓘ

CycB/CCNB1↓, 1,   RB1↑, 1,   TumCCA↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

EMT↑, 1,   ERK↓, 1,   mTOR↓, 1,   RAS↓, 1,  

Migration ⓘ

FAK↓, 1,   MMP1↓, 1,   MMP13↓, 1,   MMP2↓, 1,   MMP3↓, 1,   MMP9↓, 1,   Rho↓, 1,   ROCK1↓, 1,   TGF-β↓, 1,   TumCI↓, 1,   TumCP↓, 1,   TumMeta↓, 1,   uPA↓, 1,  

Angiogenesis & Vasculature ⓘ

angioG↓, 1,  

Immune & Inflammatory Signaling ⓘ

CD4+↓, 1,   COX2↓, 2,   IL1↓, 1,   IL6↓, 1,   Inflam↓, 1,   MCP1↓, 1,   NF-kB↓, 2,   PGE2↓, 1,   TNF-α↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 2,   ChemoSen↑, 1,   eff↑, 2,  

Clinical Biomarkers ⓘ

IL6↓, 1,  

Functional Outcomes ⓘ

AntiCan↑, 1,   AntiTum↑, 1,   RenoP↑, 1,  
Total Targets: 61

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 1,   Catalase↑, 1,   GPx↑, 1,   ROS↓, 1,  
Total Targets: 4

Scientific Paper Hit Count for: CDC25, Cell Division Cycle 25
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:58  Cells:%  prod#:%  Target#:526  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page